OR AKIVA, Israel, Dec. 9, 2025 /PRNewswire/ — Allmed Solutions (TASE: ALMD), an Israeli biomedical company, has announced a dramatic success in a first-in-human trial, achieving the full replacement of a major heart valve in critically ill patients via a minimally invasive catheterization procedure, entirely eliminating the need for high-risk open-chest surgery.
NEWPORT BEACH, Calif., Dec. 9, 2025 /PRNewswire/ — Medit, a global leader in 3D intraoral scanning and digital dentistry solutions, today announced the launch of AuraVue, a next-generation visualization and consultation platform that integrates Overjet’s AI technology to deliver real-time diagnostic insights and clearer patient communication.
TEL AVIV, Israel, Dec. 9, 2025 /PRNewswire/ — MedINT today announced the commercial launch of the first human-in-the-loop medical AI platform designed to return full control of evidence review and treatment decisions to clinicians managing complex patients. The system maintains clinician control at every step by delivering patient-specific evidence summaries that support clinical judgment without replacing it.
MIT researchers discover how an immune system molecule triggers neurons to shut down social behavior in mice modeling infection.
Medical Microinstruments (MMI) announced today that the FDA granted 510(k) clearance for its NanoWrist surgical robot instruments.
The approval is said to cover a range of clinical indications and supports use in both acute and chronic patients.
In a new leap for neurobiology and bioelectronics, Northwestern University scientists have developed a wireless device that uses light to send information directly to the brain—bypassing the body’s natural sensory pathways.
NES ZIONA, Israel, Dec. 8, 2025 /PRNewswire/ — EyeYon Medical Ltd., a global leader in ophthalmic innovation, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to initiate a U.S. clinical study of EndoArt®, the world’s first synthetic endothelial layer for the treatment of chronic corneal edema. EndoArt® is currently designated by the FDA as a Breakthrough Device.
15-minute test developed at Northwestern provides results up to 75% faster than current rapid tests
Using a versatile problem-solving framework, researchers show how early relapse in lymphoma patients influences their chance for survival.